AI filing briefs · archive

8-K filings in September 2026, explained

1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,853 briefs match

newest first · times in ET

RCKTROCKET PHARMACEUTICALS, INC. Sep 15, 7:06 AM ET

Rocket Pharmaceuticals says FDA aligns on RP-A501 Danon disease pivotal trial path

Positive legal/regulatory Written later 7.01

Rocket Pharmaceuticals said the U.S. Food and Drug Administration confirmed continued enrollment and dosing under a modified protocol for its global pivotal Phase 2 trial of RP-A501 in Danon disease, along with a 12-patient pivotal population and established 12-month co-primary endpoints. The alignment is a regulatory milestone for the program, and the company said it expects to complete dosing of the remaining patients by mid-2027.

FDA confirmed a pivotal population of 12 male patients treated at the recalibrated dose of 3.8 × 10¹³ GC/kg.
The first three patients treated under the modified protocol count toward the 12-patient pivotal population, leaving nine to be enrolled and treated.
Primary assessment at 12 months uses myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index as co-primary endpoints.
Rocket plans a Danon disease program webinar on October 6, 2026, at 4:30 p.m. ET.

Read the filing on SEC.gov ↗

HUBGHub Group, Inc. Sep 15, 6:02 AM ET

Hub Group expects H1 2026 operating loss and Nasdaq delisting notice amid restatement

Negative legal/regulatory Written later 1.01 2.02 5.02 7.01

Hub Group filed preliminary, unaudited first and second quarter 2026 results and said it expects an operating loss for the first half of 2026 before one-time charges, while revenue is expected to be $1.70 billion to $1.80 billion. The company also said it expects to receive a Nasdaq Staff Delisting Determination, and it plans to request a hearing, because its restated financial statements and delayed 10-K and 10-Q filings are not yet complete, which matters to shareholders because the outcome could affect whether the Class A stock keeps trading on Nasdaq.

Company expects an operating loss for the first half of 2026 before one-time charges; it did not provide an operating income or loss range.
Full-year 2026 consolidated operating revenue is estimated at $3.6 billion to $3.8 billion.
Nasdaq exception to file delayed reports ran through September 14, 2026; the company expects to complete the filings in the fourth quarter of 2026.
David Yeager returned as Chairman and CEO; Patrick O'Donnell will become CFO after the 2025 Form 10-K is filed.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.